[go: up one dir, main page]

MX395730B - Uso de lavados alcalinos durante la cromatografia para remover impurezas. - Google Patents

Uso de lavados alcalinos durante la cromatografia para remover impurezas.

Info

Publication number
MX395730B
MX395730B MX2017011121A MX2017011121A MX395730B MX 395730 B MX395730 B MX 395730B MX 2017011121 A MX2017011121 A MX 2017011121A MX 2017011121 A MX2017011121 A MX 2017011121A MX 395730 B MX395730 B MX 395730B
Authority
MX
Mexico
Prior art keywords
remove impurities
protein
interest
during chromatography
chromatography matrix
Prior art date
Application number
MX2017011121A
Other languages
English (en)
Other versions
MX2017011121A (es
Inventor
Jue Wang
Krina Patel
Neil E Jaffe
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2017011121A publication Critical patent/MX2017011121A/es
Publication of MX395730B publication Critical patent/MX395730B/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/50—Conditioning of the sorbent material or stationary liquid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere en ciertas modalidades, a un método para purificar una proteína de interés a partir de una mezcla la cual comprende la proteína de interés y uno o más contaminantes, tal método comprende: a) someter la mezcla a una primera matriz de cromatografía, en donde la proteína de interés se une a la primera matriz de cromatografía; b) poner en contacto la primera matriz de cromatografía con una primera solución de lavado la cual tiene un pH de al menos 9.0, y no comprende arginina o un derivado de arginina; y c) eluir la proteína de interés a partir de la primera matriz de cromatografía en una solución de elución.
MX2017011121A 2015-03-13 2016-03-11 Uso de lavados alcalinos durante la cromatografia para remover impurezas. MX395730B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562132974P 2015-03-13 2015-03-13
PCT/US2016/021984 WO2016149088A1 (en) 2015-03-13 2016-03-11 Use of alkaline washes during chromatography to remove impurities

Publications (2)

Publication Number Publication Date
MX2017011121A MX2017011121A (es) 2017-11-28
MX395730B true MX395730B (es) 2025-03-25

Family

ID=55699796

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011121A MX395730B (es) 2015-03-13 2016-03-11 Uso de lavados alcalinos durante la cromatografia para remover impurezas.

Country Status (13)

Country Link
US (2) US10695693B2 (es)
EP (2) EP4194071A1 (es)
JP (1) JP6807859B2 (es)
KR (1) KR102490956B1 (es)
CN (1) CN107636005B (es)
AU (2) AU2016233557B2 (es)
BR (1) BR112017018365A2 (es)
CA (1) CA2978095C (es)
EA (1) EA035635B1 (es)
IL (1) IL254372B (es)
MX (1) MX395730B (es)
SG (2) SG10201908027QA (es)
WO (1) WO2016149088A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073401A1 (en) * 2014-11-03 2016-05-12 Bristol-Myers Squibb Company Use of caprylic acid precipitation for protein purification
MX395730B (es) 2015-03-13 2025-03-25 Bristol Myers Squibb Co Uso de lavados alcalinos durante la cromatografia para remover impurezas.
WO2018140887A1 (en) 2017-01-30 2018-08-02 Regeneron Pharmaceuticals, Inc. Method for reducing bioburden in chromatography
KR102882390B1 (ko) * 2018-06-19 2025-11-05 브리스톨-마이어스 스큅 컴퍼니 크로마토그래피를 사용하여 단백질을 정제하는 방법
MY207066A (en) * 2018-08-17 2025-01-28 Regeneron Pharma Method and chromatography system for determining amount and purity of a multimeric protein
KR102270048B1 (ko) * 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
CA3116717A1 (en) * 2018-10-31 2020-05-07 Regeneron Pharmaceuticals, Inc. Method and system of identifying and quantifying a protein
WO2020125757A1 (en) * 2018-12-21 2020-06-25 Wuxi Biologics (Shanghai) Co., Ltd. A method for improving aggregate removal by protein a chromatography
KR20210116502A (ko) 2019-01-16 2021-09-27 리제너론 파아마슈티컬스, 인크. 항체 단편화를 동정 및 정량화하는 방법 및 시스템
CN109870428A (zh) * 2019-01-21 2019-06-11 江苏华泰疫苗工程技术研究有限公司 一种基于表面等离子共振技术的抗体定量检测方法
GB201904741D0 (en) * 2019-04-04 2019-05-22 Glaxosmithkline Ip Dev Ltd Novel process
KR20220066393A (ko) 2019-09-24 2022-05-24 리제너론 파아마슈티컬스, 인크. 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법
US20220396598A1 (en) * 2019-10-14 2022-12-15 Pierce Biotechnology, Inc. Peptide purification formulations and methods
US20240262928A1 (en) * 2020-03-27 2024-08-08 Haemalogix Pty Ltd Composition and Method
WO2025178923A1 (en) * 2024-02-20 2025-08-28 Exelixis, Inc. Methods for protein purification

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
CA1326940C (en) * 1987-02-26 1994-02-08 Michael Dustin Purification of lfa-3
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
CA1323567C (en) * 1987-10-05 1993-10-26 Gene R. Nathans Method for purification of antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) * 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
ES2292682T3 (es) * 1998-05-06 2008-03-16 Genentech, Inc. Purificacion de anticuerpos mediante cromatografia de intercambio ionico.
ATE354655T1 (de) 1999-08-24 2007-03-15 Medarex Inc Humane antikörper gegen ctla-4 und deren verwendungen
EP1916303B1 (en) 2000-11-30 2013-02-27 Medarex, Inc. Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice
DE60325334D1 (de) 2002-02-05 2009-01-29 Genentech Inc Proteinaufreinigung
US7763706B1 (en) 2003-07-17 2010-07-27 Campina B.V. Arginine/lysine-enriched peptides
EP1678208B1 (en) 2003-10-27 2013-05-15 Wyeth LLC Removal of high molecular weight aggregates using hydroxyapatite chromatography
US8058410B2 (en) * 2005-04-26 2011-11-15 Sandoz Ag Affinity ligands
US8263750B2 (en) * 2006-03-16 2012-09-11 Amgen Inc. Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
WO2008025748A1 (en) * 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-containing proteins
KR20090064377A (ko) * 2006-09-08 2009-06-18 와이어쓰 친화성 크로마토그래피를 사용하는 단백질 정제에 있어서 아르기닌 세척
HRP20150282T4 (hr) * 2007-10-30 2018-08-10 Genentech, Inc. Purifikacija protutijela pomoću kromatografije kationskom izmjenom
RU2520838C2 (ru) * 2008-10-20 2014-06-27 Эббви Инк Выделение и очистка антител с использованием аффинной хроматографии на основе белка а
PT2513134T (pt) 2009-12-18 2017-12-14 Novartis Ag Solução de lavagem e método para cromatografia de afinidade
JP2012001462A (ja) 2010-06-15 2012-01-05 Kaneka Corp 抗体精製用カラム
PT2714714T (pt) 2011-06-01 2018-10-22 Novartis Ag Solução de lavagem e método para cromatografia de afinidade
TWI596107B (zh) * 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
MX381087B (es) * 2013-12-26 2025-03-12 Mitsubishi Tanabe Pharma Corp Anticuerpo monoclonal neutralizador de anti-il-33 humana.
WO2016031932A1 (ja) * 2014-08-27 2016-03-03 田辺三菱製薬株式会社 アルカリ洗浄によるＦｃ領域を有するタンパク質の製造方法
MX395730B (es) 2015-03-13 2025-03-25 Bristol Myers Squibb Co Uso de lavados alcalinos durante la cromatografia para remover impurezas.

Also Published As

Publication number Publication date
KR20170125948A (ko) 2017-11-15
AU2016233557A1 (en) 2017-11-02
CN107636005A (zh) 2018-01-26
AU2021221870A1 (en) 2021-09-23
MX2017011121A (es) 2017-11-28
JP2018510867A (ja) 2018-04-19
US12157073B2 (en) 2024-12-03
SG10201908027QA (en) 2019-10-30
US20200282332A1 (en) 2020-09-10
CA2978095C (en) 2022-02-15
WO2016149088A1 (en) 2016-09-22
KR102490956B1 (ko) 2023-01-19
EA201792012A1 (ru) 2018-01-31
SG11201707330RA (en) 2017-10-30
EP3268100A1 (en) 2018-01-17
BR112017018365A2 (pt) 2018-04-10
CN107636005B (zh) 2021-07-16
US10695693B2 (en) 2020-06-30
EP4194071A1 (en) 2023-06-14
JP6807859B2 (ja) 2021-01-06
AU2016233557B2 (en) 2021-06-24
IL254372A0 (en) 2017-11-30
CA2978095A1 (en) 2016-09-22
EA035635B1 (ru) 2020-07-17
IL254372B (en) 2022-05-01
US20180078876A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
MX395730B (es) Uso de lavados alcalinos durante la cromatografia para remover impurezas.
MX2016017115A (es) Metodos y reactivos para la purificacion de proteinas.
MX392628B (es) Amortiguador de lavado de cromatografia de afinidad.
PE20142451A1 (es) Composiciones de conjugados de xten y metodos para realizar las mismas
JOP20170041B1 (ar) اجسام مضادة ضد vista (b7h5)
MX2019015304A (es) Amortiguador de lavado para cromatografia de intercambio cationico.
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
CU20170039A7 (es) Método de purificación del anticuerpo humanizado 9e4
BR112014015101A2 (pt) cromatografia de membrana de troca iônica
WO2015191911A3 (en) Protein enriched microvesicles and methods of making and using the same
WO2015195453A3 (en) Methods for increasing the capacity of flow-through processes
SG194460A1 (en) Wash solution and method for affinity chromatography
CR20200234A (es) POLIPÉPTIDO PARA LA ESCISIÓN DE ZEARALENONA Y/O DERIVADOS DE LA ZEARALENONA, POLINUCLEÓTIDOS AISLADOS DEL MISMO, Y ADITIVO POLIPÉPTIDO QUE CONTIENE, USO DE DICHO POLIPÉPTIDO Y MÉTODO (Divisional 2016-0128)
AR074015A1 (es) Purificacion de proteinas acidas utilizando cromatografia de hidroxiapatita ceramica
TR201911082T4 (tr) K vitaminine bağımlı proteinlerin saflaştırılması için bir işlem.
CL2020000087A1 (es) Cromatografía.
EP4389757A3 (en) Methods for purifying antibodies
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
MX388197B (es) Método para la reducción de proteínas de células hospederas en cromatografía de afinidad.
AR104358A1 (es) Método para la purificación de proteínas
EA201892643A1 (ru) Способ очистки и активации ботулинического нейротоксина
MY181081A (en) Method for purifying antibody having low isoelectric point
BR112017025872A2 (pt) proteínas de ligação multiespecíficas
WO2015036917A3 (en) Methods and kits for quantifying the removal of mock virus particles from a purified solution